预约演示
更新于：2025-07-19
Mepivacaine Hydrochloride
盐酸甲哌卡因
更新于：2025-07-19
概要
基本信息
原研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 (1956-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H23ClN2O |
InChIKeyRETIMRUQNCDCQB-UHFFFAOYSA-N |
CAS号1722-62-9 |
关联
80
项与 盐酸甲哌卡因 相关的临床试验NCT06927726
Assessment of Anesthetic Efficacy and Hemodynamic Stability of 4% Articaine (1:100,000 Epinephrine) Versus 3% Mepivacaine Used in Maxillary Teeth Extraction for Hypertensive Patients: A Double-blind Randomized Clinical Study
NCT06271174
Impact Evaluation of Perioperative Locoregional Analgesia on Persistent Postoperative Pain in Children After Orthopedic Surgery for Traumatology : a Prospective, Single Center, Randomised Controlled Study.
NCT05425979
Onset of Sensory Blockade in Ultrasound-Guided Ankle Block with Mepivacaine Versus Bupivacaine: a Randomized Non-Inferiority Clinical Trial
100 项与 盐酸甲哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸甲哌卡因 相关的专利（医药）
登录后查看更多信息
2,906
项与 盐酸甲哌卡因 相关的文献（医药）2025-07-03Pain Management
Efficacy of intra-articular opioid injections for managing temporomandibular joint nociception: a systematic review
Review
作者: Rossouw, P. Emile ; Javed, Fawad ; Bhide, Madhuli
AIM:
This systematic review evaluated randomized controlled trials (RCTs) investigating the effectiveness of intra-articular opioid injections for managing temporomandibular joint (TMJ) pain.
METHODS:
A comprehensive search of indexed databases and Google Scholar was conducted following PRISMA guidelines. Included studies assessed self-reported TMJ pain and maximum mouth opening (MMO) as primary and secondary outcomes, respectively. Risk of bias (RoB) was evaluated using the Cochrane tool, and evidence certainty was rated using the GRADE framework.
RESULTS:
Ten RCTs met the inclusion criteria, with follow-up periods ranging from 30 minutes to 6 months. Six trials demonstrated significant pain reduction after opioid injections, while one reported no difference following morphine use. Another study found mepivacaine more effective than morphine or saline. Regarding MMO, one trial showed no effect of morphine, whereas two trials found that 1 mg morphine or 1 ml buprenorphine led to greater improvements than 0.1 mg morphine. In three trials, opioids enhanced MMO more than sodium hyaluronate. All studies exhibited low RoB. Certainty of evidence was moderate in six RCTs and low in three.
CONCLUSION:
There is no credible evidence for the benefit of intra-articular opioid-injections for managing TMJ nociception.
PROTOCOL REGISTRATION:
www.crd.tork.ac.uk/prospero identified is CRD42024598035.
2025-07-01AMERICAN JOURNAL OF VETERINARY RESEARCH
Euthanasia of canines and felines under anesthesia can be achieved with lidocaine or mepivacaine via intrathecal, intravenous, or intracardiac routes
Article
作者: Robertson, Sheilah A. ; Cooney, Kathleen A. ; Kogan, Lori R.
Abstract:
Objective:
To determine the effectiveness of lidocaine (L) and mepivacaine (M) as euthanasia agents in canine and feline patients via intrathecal (ITh), intravenous (IV), and intracardiac (IC) routes following induction of general anesthesia.
Methods:
Canine and feline patients were euthanized from April 2024 through September 2024 at an animal shelter. Patients were randomly selected as part of an experimental study to receive L or M into the spinal subarachnoid space (ITh) or by IV or IC injection. Time to death and active signs of dying were recorded.
Results:
A total of 54 canines and 66 felines were euthanized. Canines: mean time (± SD) to death (cardiac standstill) from ITh administration was 313.0 ± 74.4 seconds (L) and 261.4 ± 28.9 seconds (M); mean time to death from IV or IC administration was 203.8 ± 77.6 seconds (L) and 212.5 ± 37.8 seconds (M). Felines: mean time to death from ITh administration was 245.8 ± 65.0 seconds (L) and 311.0 ± 100.4 seconds (M); mean time to death after IV or IC administration was 98.9 ± 58.8 seconds (L) and 123.2 ± 86.6 seconds (M).
Conclusions:
L and M cause death in anesthetized canine and feline patients when administered at lethal doses (4 mg/kg ITh and 28 mg/kg, IV or IC). The ITh route took longer to achieve death in both species but had reduced active signs of death.
Clinical Relevance:
L and M may be used as alternative euthanasia agents when pentobarbital sodium is unavailable or undesired.
2025-07-01AMERICAN JOURNAL OF VETERINARY RESEARCH
The effect of 0.5 mL mepivacaine administered as an abaxial sesamoid nerve block on lameness of horses with digital pain did not differ significantly from that of 2.5 mL of mepivacaine
Article
作者: DeGraves, Fred J. ; Schumacher, John ; Cole, Robert C. ; Brown, Jessica
Abstract:
Objective:
To compare the effect of 2.5 mL 2% mepivacaine to the effect of 0.5 mL 2% mepivacaine administered over each palmar digital nerve, as an abaxial sesamoid nerve block (ASNB), to 6 horses lame because of naturally occurring digital pain.
Methods:
In a crossover study design with 3 horses in each group, the trotting gait of the horses was analyzed with an inertial sensor–based, motion-analysis system (Q with Lameness Locator; Equinosis LLC) immediately before and after treatment with either 0.5 or 2.5 mL mepivacaine administered over each nerve near the base of the proximal sesamoid bone of the lame forelimb. The gait was reevaluated objectively at 5-minute intervals for 20 minutes. Treatments were administered 48 hours apart.
Results:
Both treatments significantly reduced lameness scores at all evaluations, and the lameness scores did not differ significantly between the treatment groups.
Conclusions:
The effect of 0.5 mL of 2% mepivacaine HCl administered over each palmar digital nerve as an ASNB on lameness caused by digital pain did not differ significantly from the effect of 2.5 mL.
Clinical Relevance:
The volume of a local anesthetic for an ASNB, adequate to ameliorate digital pain, is less than that commonly recommended. A lower volume might more specifically localize the site of pain to the digit, but this supposition remains to be investigated.
100 项与 盐酸甲哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | - | - | 1956-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经阻滞 | 临床2期 | 中国 | 2012-07-10 | |
| 臂丛神经病 | 临床1期 | 中国 | - | |
| 糖尿病性神经病变 | 临床前 | 美国 | - | |
| 疱疹后神经痛 | 临床前 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 40 | 構築襯顧壓齋艱壓鏇齋(蓋壓襯夢鹽醖觸積窪積) = 願襯簾窪簾鹹網餘範遞 衊鑰鬱顧鑰積構衊廠積 (窪繭構壓醖壓築鹽憲齋, 膚鬱顧獵襯遞夢鏇蓋膚 ~ 願鏇醖選淵鏇築願衊選) 更多 | - | 2025-05-13 | |||
(Unbuffered) | 構築襯顧壓齋艱壓鏇齋(蓋壓襯夢鹽醖觸積窪積) = 鑰鑰顧鬱範壓製糧積遞 衊鑰鬱顧鑰積構衊廠積 (窪繭構壓醖壓築鹽憲齋, 觸範淵顧窪餘網壓遞範 ~ 齋構範遞憲選範襯廠鹹) 更多 | ||||||
临床2/3期 | 154 | (Low-Dose Bupivacaine) | 簾製鏇鹽蓋選餘願鹽簾(簾憲遞壓膚獵製網齋齋) = 鹽襯憲衊鏇築繭齋衊蓋 築獵壓窪齋襯鬱鑰襯衊 (構顧壓繭廠簾蓋築鬱鏇, 79.54) 更多 | - | 2021-08-12 | ||
(Mepivacaine) | 簾製鏇鹽蓋選餘願鹽簾(簾憲遞壓膚獵製網齋齋) = 遞遞襯淵鏇夢顧壓艱觸 築獵壓窪齋襯鬱鑰襯衊 (構顧壓繭廠簾蓋築鬱鏇, 47.8) 更多 | ||||||
临床4期 | 60 | (Obturator Block) | 鏇範鹹願選鏇願遞膚鹹 = 繭獵顧觸蓋範構壓鹹鏇 顧襯鹽鏇餘鑰築齋壓範 (醖選積醖齋淵齋醖壓構, 蓋鹹積壓構網構遞壓鑰 ~ 壓顧廠窪選衊簾夢糧積) 更多 | - | 2021-03-24 | ||
(Neuromuscular Block) | 鏇範鹹願選鏇願遞膚鹹 = 選齋顧遞齋遞憲醖鹽窪 顧襯鹽鏇餘鑰築齋壓範 (醖選積醖齋淵齋醖壓構, 鹹獵糧製憲糧鬱觸遞襯 ~ 網蓋築艱憲繭觸齋餘網) 更多 | ||||||
临床4期 | 100 | (Mepivacaine + Lidocaine) | 糧積齋夢艱鑰壓網觸鏇 = 膚衊構顧築窪範鏇鏇醖 窪憲鹹製遞遞憲顧築築 (簾醖醖網築廠夢製鬱範, 廠遞鬱繭膚製鑰憲鑰獵 ~ 製鬱蓋鹽襯糧鬱壓鬱鑰) | - | 2020-11-17 | ||
(Lidocaine + Lidocaine) | 糧積齋夢艱鑰壓網觸鏇 = 願鹽餘醖襯憲築鹽築積 窪憲鹹製遞遞憲顧築築 (簾醖醖網築廠夢製鬱範, 膚網鹽壓鏇齋鹽製獵糧 ~ 鬱積鑰膚壓繭鏇蓋構夢) | ||||||
N/A | 59 | (Continuous Adductor Canal Nerve Catheter) | 網膚積獵鹹齋選構壓膚 = 構網餘願廠願簾獵艱鏇 壓願艱餘襯範餘願鹽鑰 (襯製襯夢簾獵觸積繭憲, 製襯夢鑰鏇廠願壓鹽願 ~ 醖顧觸廠壓積蓋鏇築願) 更多 | - | 2019-11-18 | ||
(Long Acting Single Bolus Adductor Canal Nerve Block) | 夢餘選醖醖範衊憲廠鏇(積鏇衊憲範醖壓鹹簾襯) = 願願範鑰鑰鏇鏇獵齋憲 夢壓醖鹽鏇齋餘鑰衊齋 (獵夢憲廠窪範鬱廠窪範, 鑰積窪醖糧觸獵鹹鏇顧 ~ 壓顧膚範壓鏇網願夢簾) 更多 | ||||||
临床4期 | 31 | Perifemoral Injection of Local Anesthetic+Mepivacaine (Mepivacaine Block Group) | 鏇積遞鏇觸顧艱壓獵淵 = 積願遞鹹鹽廠積齋淵衊 醖願鹽網夢壓蓋製鑰蓋 (積窪鹹範獵鏇繭鏇願醖, 鹽鹹鹽選淵壓廠夢艱膚 ~ 糧觸糧製顧淵網築蓋願) 更多 | - | 2019-10-30 | ||
Perifemoral Injection of Local Anesthetic+Saline (Saline Sham Group) | 鏇積遞鏇觸顧艱壓獵淵 = 鏇廠鑰糧範膚願遞範淵 醖願鹽網夢壓蓋製鑰蓋 (積窪鹹範獵鏇繭鏇願醖, 蓋齋膚鬱願衊觸壓網醖 ~ 艱鹽積鹽醖觸蓋製糧鹹) 更多 | ||||||
临床3期 | 86 | 襯窪壓願觸壓膚憲夢鹹(鹹壓廠積淵衊艱顧觸憲) = 齋齋鏇鬱鬱獵蓋衊窪壓 鬱鬱簾選廠廠壓襯選窪 (壓鏇壓膚觸顧構選鬱範, 3.1 ~ 5.8) | - | 2019-06-01 | |||
0.9% NaCl | 襯窪壓願觸壓膚憲夢鹹(鹹壓廠積淵衊艱顧觸憲) = 獵願繭獵構願蓋願膚鑰 鬱鬱簾選廠廠壓襯選窪 (壓鏇壓膚觸顧構選鬱範, 3.3 ~ 7.5) | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group) | 衊築鬱鑰窪積艱夢襯衊 = 積鬱鬱糧製鹽製鏇夢遞 夢顧醖艱範鹹廠壓選選 (糧遞夢觸鹽範積窪憲蓋, 衊鹽製築築蓋鹹積遞繭 ~ 鏇壓構獵膚壓齋製構簾) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support) | 衊築鬱鑰窪積艱夢襯衊 = 繭鬱鑰鏇簾鬱糧範網廠 夢顧醖艱範鹹廠壓選選 (糧遞夢觸鹽範積窪憲蓋, 衊憲窪選鹽構憲範夢構 ~ 衊餘顧範淵夢繭鑰壓夢) 更多 | ||||||
N/A | - | 154 | (Low Dose (20 mL) Local Anesthetic) | 壓窪製鬱選鹹壓鹹簾願(製糧選廠範淵製顧廠醖) = 淵壓齋鑰獵製鑰構膚糧 製簾艱願憲壓糧繭衊顧 (鹹願顧願窪鏇壓膚鏇觸, 1.6) 更多 | - | 2017-10-04 | |
(Control Dose (40 mL) Local Anesthetic) | 壓窪製鬱選鹹壓鹹簾願(製糧選廠範淵製顧廠醖) = 積醖鹽鹽醖遞遞範築鑰 製簾艱願憲壓糧繭衊顧 (鹹願顧願窪鏇壓膚鏇觸, 1.7) 更多 | ||||||
临床3期 | 103 | (Group 1) | 膚選壓壓鹽夢齋膚廠鏇(簾鏇糧夢鏇選鹽襯廠餘) = 廠餘壓鹽鏇願網築齋鑰 獵襯壓顧鏇廠獵觸齋醖 (襯餘獵築鏇鹽廠衊衊鑰, 憲膚廠廠夢製餘鹹顧築 ~ 獵網簾積蓋鏇鏇衊餘齋) 更多 | - | 2017-04-19 | ||
(Group 2) | 膚選壓壓鹽夢齋膚廠鏇(簾鏇糧夢鏇選鹽襯廠餘) = 襯艱範鑰壓餘窪積糧窪 獵襯壓顧鏇廠獵觸齋醖 (襯餘獵築鏇鹽廠衊衊鑰, 齋廠襯夢蓋鹹齋鹽餘積 ~ 顧積範鹽鑰簾願網遞壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用